Life Science Investing Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
Life Science Investing Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
Life Science Investing Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS
Life Science Investing Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic , and Pharmacodynamic Data
Life Science Investing Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients
Life Science Investing Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study
Life Science Investing Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
Life Science Investing Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
Life Science Investing Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
Life Science Investing Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
Life Science Investing Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
TomaGold Intercepts 6.68% ZnEq (1.57 g/t AuEq) over 48.05 Metres, including 39.03% ZnEq (9.15 g/t AuEq) over 2.90 Metres at Berrigan Mine and Identifies a Major Hydrothermal Footprint
Apollo Silver Announces Correction to Warrant Terms of $25 Million Strategic Investment by Eric Sprott and Jupiter Asset Management
